Jean-Luc P.

Investigates targeted and immunologic strategies for gastrointestinal and renal cancers, including colorectal cancer and metastatic renal cell carcinoma.

• Regorafenib‑metronomic chemotherapy combos
• ctDNA‑guided adjuvant therapy
• PD‑L1 stratified checkpoint inhibitor trials
• FOLFIRI‑bevacizumab versus trifluridine/tipiracil
• VEGFR‑TKI combinations

Emphasis on personalized treatment selection based on molecular profiling.

Addresses atherosclerotic disease, hypertension, and heart failure in the context of type 2 diabetes and chronic kidney impairment.

• Diuretic‑based algorithms for uncontrolled hypertension
• Vicadrostat‑empagliflozin cardiovascular outcome trial
• Low‑dose colchicine for recurrent vascular events
• Management of myocardial infarction and coronary syndrome
• Blood pressure lowering in CKD

Integrates cardiovascular risk reduction with metabolic control.

Explores vaccine efficacy and antimicrobial strategies for viral, bacterial, and autoimmune conditions such as HPV and early syphilis.

• Non‑avalent HPV vaccine for recalcitrant warts
• Doxycycline versus benzathine penicillin for early syphilis
• Prolonged anticoagulation in autoimmune hemolytic anemia
• Interferon‑γ to prevent ICU‑acquired infections
• Immunomodulation in sustained immunosuppression

Trials incorporate both prophylactic and therapeutic immunologic approaches.

Concentrates on acute and chronic cerebrovascular events, including ischemic stroke and transient ischemic attack.

• Secondary prevention after cerebral infarction
• Risk stratification for transient ischemic attack patients
• Vascular imaging to guide antithrombotic therapy
• Integration of cardiac disease management with stroke care
• Outcomes research in stroke survivors

Collaborative efforts link neurology and cardiology units at the host institution.